Han Xuechang, Xing Qunzhi, Li Yu, Sun Junjun, Ji Huihui, Huazheng Pan, Jun Liang
Department of Anesthesiology, The First Affiliated Hospital of Henan Science and Technology University, Luoyang, China.
Hepatogastroenterology. 2012 Oct;59(119):2285-9. doi: 10.5754/hge12096.
BACKGROUND/AIMS: We conducted a case-control study in China to clarify the association between XRCC1-Arg-399Gin polymorphism and HCC risk.
A total of 150 cases and 158 controls were selected from May 2008 to May 2010. XRCC1-Arg399Gin and XRCC3-Thr241Met polymorphisms were based upon duplex polymerase-chain-reaction with the confronting-two-pair primer (PCR-CTPP) method. All analysis was performed by using the STATA statistical package.
A significant increased risk of HCC was associated with XRCC1 399Arg/Gin, and a heavy risk of HCC was also found in individuals with XRCC3 241Met/Met genotypes. A significant association was found between positive HBsAg and Arg/Gin. XRCC3 Thr/Met genotypes had a significant positive association with HBsAg (+) and a heavy risk of HCC was found in HBsAg (+) individuals with XRCC3 Met/Met genotype. Individuals carrying XRCC1 Gin/Gin genotypes showed significantly lower median survival than XRCC1 Arg/ Arg genotypes and significant hazard ratio (HR=l.38, 95% CI=l.04-1.84) was found. Meanwhile, we found a moderate HR for XRCC3 Thr/Met (HR=l.96, 95% CI=l.23-3.15) and a heavy HR for XRCC3 Met/Met (HR=2.98, 95% CI=1.77-7.54).
In conclusion, we observed that XRCC1-Arg399Gln and XRCC3-Thr241Met polymorphism is associated with susceptibility to HCC and XRCC1 Gin allele and XRCC3 Met allele genotype showed significant poor prognosis of HCC.
背景/目的:我们在中国开展了一项病例对照研究,以阐明XRCC1基因第399位密码子精氨酸突变为谷氨酰胺(XRCC1-Arg-399Gln)多态性与肝癌风险之间的关联。
2008年5月至2010年5月共选取了150例病例和158例对照。采用双引物聚合酶链反应(PCR-CTPP)方法检测XRCC1-Arg399Gln和XRCC3-Thr241Met多态性。所有分析均使用STATA统计软件包进行。
XRCC1基因399位密码子为精氨酸/谷氨酰胺(Arg/Gln)与肝癌风险显著增加相关,XRCC3基因241位密码子为甲硫氨酸/甲硫氨酸(Met/Met)基因型个体患肝癌的风险也很高。乙肝表面抗原(HBsAg)阳性与Arg/Gln之间存在显著关联。XRCC3基因苏氨酸/甲硫氨酸(Thr/Met)基因型与HBsAg(+)呈显著正相关,XRCC3基因Met/Met基因型的HBsAg(+)个体患肝癌的风险很高。携带XRCC1基因Gln/Gln基因型的个体中位生存期显著低于XRCC1基因Arg/Arg基因型,且发现显著的风险比(HR=1.38,95%可信区间[CI]=1.04-1.84)。同时,我们发现XRCC3基因Thr/Met的风险比适中(HR=1.96,95%CI=1.23-3.15),XRCC3基因Met/Met的风险比很高(HR=2.98,95%CI=1.77-7.54)。
总之,我们观察到XRCC1-Arg399Gln和XRCC3-Thr241Met多态性与肝癌易感性相关,XRCC1基因Gln等位基因和XRCC3基因Met等位基因基因型显示肝癌预后显著较差。